Zobrazeno 1 - 9
of 9
pro vyhledávání: '"L R, Lopetuso"'
Autor:
L Masi, V Petito, M Fidaleo, I Palucci, F Del Chierico, V Ivagnes, A Mercuri, C Graziani, L R Lopetuso, A Armuzzi, A Gasbarrini, G Pani, F Scaldaferri
Publikováno v:
Journal of Crohn's and Colitis. 16:i136-i139
Background The putative Ergothioneine Transporter, SLC22A4/OCTN1, is expressed in the intestine and monocytes/macrophages, and its widely represented missense variant L503F (0.4 Minor Allele Frequency in Caucasians) has been found to be associated wi
Autor:
L R Lopetuso, G Privitera, L Di Martino, F Scaldaferri, A Gasbarrini, F Cominelli, C De Salvo, T Pizarro
Publikováno v:
Journal of Crohn's and Colitis. 17:i261-i262
Background Colorectal cancer associated to chronic colitis (CAC) has a different pathogenesis compared to sporadic or familial colorectal cancer and represents the major complication of IBD. IL-33 and its receptor, ST2, are important factors in the p
Autor:
D Napolitano, A Cocchieri, N Orgiana, C Fanali, A Poscia, E Schiavoni, T Bernabei, V Amatucci, L Turchini, E Durini, M Strazzeri, L Laterza, L R Lopetuso, V Mora, A Papa, D Pugliese, A Gasbarrini, F Scaldaferri
Publikováno v:
Journal of Crohn's and Colitis. 17:i1047-i1048
Background Inflammatory Bowel Disease (IBD) management requires a multidisciplinary team, in which nurses have a pivotal role. Although patient care is the main focus of all clinical actions, satisfaction with healthcare professionals is an aspect of
Autor:
F. Scaldaferri, M. Pizzoferrato, L. R. Lopetuso, T. Musca, F. Ingravalle, L. L. Sicignano, M. Mentella, G. Miggiano, M. C. Mele, E. Gaetani, C. Graziani, V. Petito, G. Cammarota, E. Marzetti, A. Martone, F. Landi, A. Gasbarrini
Publikováno v:
Gastroenterology Research and Practice, Vol 2017 (2017)
Malnutrition is a major complication of inflammatory bowel disease (IBD). This mini review is focusing on main determinants of malnutrition in IBD, the most important components of malnutrition, including lean mass loss and sarcopenia, as an emerging
Externí odkaz:
https://doaj.org/article/945da9646c7f4b36b61c8126dac52b72
Autor:
L R Lopetuso, L Vetrone, V Petito, D Pugliese, L Parisio, L Laterza, A Gasbarrini, F Scaldaferri, A Papa
Publikováno v:
Journal of Crohn's and Colitis. 17:i1023-i1023
Background IL-33/ST2 axis and gut microbiota are important factors in the pathogenesis of IBD with a potential reciprocal influence. IL-33/ST2 axis controls the mucosal healing process during intestinal inflammation. Pouchitis, after restorative proc
Autor:
F, Scaldaferri, A, Papa, D, Napolitano, G, Rizzatti, M T, Pistone, A, Poscia, M, Volpe, L R, Lopetuso, E, Schiavoni, L, Guidi, E, Gaetani, G, Holleran, G, Cammarota, G, Rapaccini, D, Pugliese, V, Ojetti, F, Franceschi, A, Armuzzi, A, Gasbarrini
Publikováno v:
European review for medical and pharmacological sciences. 25(18)
The management of Inflammatory Bowel Disease (IBD) has changed significantly in recent years, mainly due to the introduction of biologic medications, however, other factors may also have a role. The aim of this study was to evaluate the evolution of
Autor:
F R, Ponziani, F, Scaldaferri, M, De Siena, F, Mangiola, M V, Matteo, S, Pecere, V, Petito, F Paroni, Sterbini, L R, Lopetuso, L, Masucci, G, Cammarota, M, Sanguinetti, A, Gasbarrini
Publikováno v:
Beneficial microbes. 11(6)
Compositional and functional alterations of the gut microbiota are involved in the pathogenesis of several gastrointestinal diseases. Rifaximin is often used to induce disease remission due to its eubiotic effects on the gut microbiota. To investigat
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19
Autor:
A, Papa, M, Covino, F, Pizzolante, L, Miele, L R, Lopetuso, V, Bove, R, Iorio, B, Simeoni, L M, Vetrone, L, Tricoli, I, Mignini, T, Schepis, A, D'Alessandro, G, Coppola, T, Nicoletti, E, Visconti, G, Rapaccini
The Coronavirus Disease 2019 (COVID-19) pandemic mainly involves respiratory symptoms, though gastrointestinal (GI) symptoms are increasingly being recognized. In this context, the presence of comorbidities appears to be associated with adverse outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1644ca3730f389ea97b330386ccfce0b
http://hdl.handle.net/10807/179105
http://hdl.handle.net/10807/179105
Autor:
P Puca, I Capobianco, V Petito, L Masi, M Fidaleo, F Del Chierico, I Palucci, L R Lopetuso, L Laterza, C R Settanni, L Parisio, S Bibbò, D Pugliese, A Armuzzi, G Pani, A Gasbarrini, F Scaldaferri
Publikováno v:
Journal of Crohn's and Colitis. 16:i396-i396
Background Ulcerative colitis is a chronic invalidating disease, whose therapeutic strategies include amino-salicylates, steroids, probiotics, immune-modulators, biologics, fecal microbiota transplantation and surgery. In clinical practice, there is